Compared to the corresponding normal tissues, EP300-AS1 expression was significantly decreased in SCLC tissues, whereas no significant differences in EP300-AS1 expression were observed in colon adenocarcinoma (COAD), stomach adenocarcinoma (STAD), liver hepatocellular carcinoma (LIHC), breast carcinoma (BRCA), or kidney renal clear cell carcinoma (KIRC) (Fig. S8a). Here, EP300 is linked to breast carcinoma.